These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21605066)

  • 21. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
    Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
    Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
    Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
    Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms.
    Or PM; Lam FF; Kwan YW; Cho CH; Lau CP; Yu H; Lin G; Lau CB; Fung KP; Leung PC; Yeung JH
    Phytomedicine; 2012 Apr; 19(6):535-44. PubMed ID: 22261394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
    Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
    Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
    Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.
    Brown HS; Ito K; Galetin A; Houston JB
    Br J Clin Pharmacol; 2005 Nov; 60(5):508-18. PubMed ID: 16236041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
    Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
    Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS; DeVane CL
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of mixtures of recombinant human cytochrome p450s as a screening model for metabolic stability in drug discovery.
    Hagen N; Olsen AK; Andersen JV; Tjørnelund J; Hansen SH
    Xenobiotica; 2002 Sep; 32(9):749-59. PubMed ID: 12396272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
    Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
    J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
    Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
    Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.
    Seguin RP; Herron JM; Lopez VA; Dempsey JL; Xu L
    Chem Res Toxicol; 2019 Dec; 32(12):2466-2478. PubMed ID: 31730751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
    Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
    Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes.
    Bourrié M; Meunier V; Berger Y; Fabre G
    Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
    Transon C; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effects of active constituents and extracts of Orthosiphon stamineus on the activities of three major human cDNA-expressed cytochrome P450 enzymes.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    Chem Biol Interact; 2011 Mar; 190(1):1-8. PubMed ID: 21276781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.